Thus, targeted inhibition of GSK-3α may provide an alternative therapeutic strategy against refractory/relapsed CML cells with TKI-resistance and possibly other leukemia cells in the context of NK cell-based therapy. This evidence concerns the gene GSK3A and chronic myelogenous leukemia, BCR-ABL1 positive.